Palbociclib is an orally bioavailable selective inhibitor of CDK4 and CDK6, kinases that regulate cell cycle progression. This compound exhibits anticancer chemotherapeutic activity in a variety of models, including renal cell carcinoma and ER+ breast cancer. Palbociclib inhibits retinoblastoma phosphorylation, preventing cells from progressing from the G1 phase to the S phase and inducing apoptosis.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.